| Year |
Citation |
Score |
| 2023 |
Chaudhry T, Krishnan V, Donaldson AE, Palmisano ZM, Basu S, Geissen NM, Karush JM, Alex GC, Borgia JA, Liptay MJ, Seder CW. Conditional survival analysis of patients with resected non-small cell lung cancer. Jtcvs Open. 16: 948-959. PMID 38204712 DOI: 10.1016/j.xjon.2023.09.010 |
0.303 |
|
| 2019 |
Seder CW, Basu S, Ramsay T, Rocco G, Blackmon S, Liptay MJ, Gilbert S. A Prolonged Air Leak Score for Lung Cancer Resection: An Analysis of the STS GTSD. The Annals of Thoracic Surgery. PMID 31323209 DOI: 10.1016/J.Athoracsur.2019.05.069 |
0.312 |
|
| 2019 |
Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, Gordon L, Karmali R. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. British Journal of Haematology. PMID 30941741 DOI: 10.1111/Bjh.15889 |
0.329 |
|
| 2019 |
Bhatt PK, Fughhi I, Basu S, Fidler MJ, Borgia JA, Bonomi PD, Batus M. Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E20721 |
0.42 |
|
| 2019 |
Kollipara R, Fughhi I, Batus M, Basu S, Borgia JA, Bonomi PD, Fidler MJ. Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E20710 |
0.421 |
|
| 2019 |
Randall M, Basu S, Batus M, Borgia JA, Bonomi PD, Fidler MJ. Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E20660 |
0.426 |
|
| 2019 |
Multani M, Tarhoni I, Fughhi I, Basu S, Batus M, Bonomi PD, Fidler MJ, Borgia JA, Shah P. Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E14061 |
0.365 |
|
| 2019 |
Lobato GC, Fidler MJ, Fialkoff JD, Multani M, Fughhi I, Wakefield C, Basu S, Batus M, Bonomi PD, Borgia JA. Associations between baseline serum biomarker levels and cachexia/precachexia in pretreated non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 37: 3054-3054. DOI: 10.1200/Jco.2019.37.15_Suppl.3054 |
0.423 |
|
| 2019 |
Tarhoni I, Fidler MJ, Fughhi I, Wakefield C, Kollipara R, Multani M, Batus M, Basu S, Lie W, Russell D, Martinson J, Landay AL, Kuzel TM, Bonomi P, Borgia JA. Abstract 404: Prognostic value of soluble and cell surface immune-checkpoint molecules in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1/-L1 immunotherapy Cancer Research. 79: 404-404. DOI: 10.1158/1538-7445.Am2019-404 |
0.301 |
|
| 2019 |
Randall M, Kollipara R, Basu S, Borgia J, Batus M, Bonomi P, Tarhoni I, Fughhi I, Fidler M. P1.05 Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on ANTI-PD-1 Therapy Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.09.062 |
0.314 |
|
| 2019 |
Lobato G, Fidler MJ, Fialkoff J, Multani M, Wakefield C, Basu S, Batus M, Bonomi P, Borgia J. MA13.01 Associations Between Baseline Serum Biomarker Levels and Cachexia/Pre-Cachexia in Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.601 |
0.419 |
|
| 2018 |
Lee HJ, Bahr JM, Bitterman P, Basu S, Sharma S, Abramowicz JS, Barua A. Polycystic Ovarian Condition May Be a Risk Factor for Ovarian Tumor Development in the Laying Hen Model of Spontaneous Ovarian Cancer. Journal of Immunology Research. 2018: 2590910. PMID 30596106 DOI: 10.1155/2018/2590910 |
0.329 |
|
| 2018 |
Seder CW, Mahon B, Hennon M, Thomas M, Levea CM, Matkowskyj KA, Krishna M, Medairos R, Macke RA, Basu S, Blasberg JD. Depth ofInvasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma. Anticancer Research. 38: 2195-2200. PMID 29599339 DOI: 10.21873/Anticanres.12461 |
0.308 |
|
| 2018 |
Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P, Borgia JA. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. Bmc Cancer. 18: 310. PMID 29558888 DOI: 10.1186/S12885-018-4193-0 |
0.434 |
|
| 2018 |
Fughhi I, Bonomi PD, Basu S, Fidler MJ, Borgia JA, Batus M. Prognostic value of neutrophil-to-lymphocyte ratio (NLR), serum albumin and sequence of immunotherapy (Immuno.) on overall survival (OS), and progression free survival (PFS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with ramucirumab plus docetaxel (RD). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E21163 |
0.435 |
|
| 2018 |
Bhatt PK, Bonomi PD, Basu S, Fidler MJ, Batus M. Mature progression-free survival (PFS) milestones in real world stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) +/- bevacizumab(Bev) followed by pem +/-bev maintenance. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E21063 |
0.427 |
|
| 2018 |
Labomascus S, Fughhi I, McDonald A, Bonomi PD, Batus M, Fidler MJ, Basu S, Borgia JA. Association of baseline and longitudinal low neutrophil-lymphocyte ratio (NLR) and high lymphocyte counts (LCs) with progression-free survival (PFS) and overall survival (OS) in real world advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with nivolumab (nivo) or pembrolizumab (pembro). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E21020 |
0.425 |
|
| 2018 |
Tarhoni IA, Fughhi I, Gerard D, Basu S, Fhied C, Lie W, Russell D, Batus M, Thakar N, Bonomi P, Fidler M, Borgia J. Abstract 5708: Associations between soluble immune checkpoint molecules and overall survival in advanced non-small cell lung cancer (NSCLC) patients treated with either anti-PD-1/-L1 monoclonal antibodies or single-agent chemotherapy Immunology. 78: 5708-5708. DOI: 10.1158/1538-7445.Am2018-5708 |
0.351 |
|
| 2018 |
Yellapa A, Bitterman P, Sharma S, Basu S, Barua A. Abstract 3810: Ovarian tumor-induced changes in macrophage phenotype are associated with tumor metastasis Cancer Research. 78: 3810-3810. DOI: 10.1158/1538-7445.Am2018-3810 |
0.316 |
|
| 2018 |
Stasik AK, Yellapa A, Bitterman P, Sharma S, Basu S, Barua A. Abstract 1689: Ovarian tumor-induced CISH expression is an immune checkpoint for NK cells Cancer Research. 78: 1689-1689. DOI: 10.1158/1538-7445.Am2018-1689 |
0.347 |
|
| 2018 |
Bhatt P, Bonomi P, Basu S, Batus M. P3.01-05 Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1565 |
0.438 |
|
| 2018 |
Labomascus S, Fughhi I, Bonomi P, Mcdonald A, Batus M, Fidler MJ, Basu S, Borgia J. P2.01-61 Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy. Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1115 |
0.34 |
|
| 2018 |
Fughhi I, Bonomi P, Fidler MJ, Basu S, Borgia J, Batus M. P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel. Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1088 |
0.359 |
|
| 2017 |
Seder CW, Arndt AT, Jordano L, Basu S, Fhied CL, Sayidine S, Chmielewski GW, Gallo K, Liptay MJ, Borgia JA. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. The Annals of Thoracic Surgery. PMID 28964418 DOI: 10.1016/J.Athoracsur.2017.06.036 |
0.42 |
|
| 2017 |
Fidler MJ, Frankenberger C, Seto R, Lobato GC, Fhied CL, Sayidine S, Basu S, Pool M, Karmali R, Batus M, Lie WR, Hayes D, Mistry J, Bonomi P, Borgia JA. Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget. 8: 58108-58121. PMID 28938541 DOI: 10.18632/Oncotarget.17510 |
0.402 |
|
| 2017 |
Karmali R, Alrifai T, Fughhi IAM, Ng R, Chukkapalli V, Shah P, Basu S, Nathan S, Szymanski-Grant K, Gordon LI, Venugopal P, Penedo FJ, Borgia JA. Impact of cachexia on outcomes in aggressive lymphomas. Annals of Hematology. PMID 28417157 DOI: 10.1007/S00277-017-2958-1 |
0.396 |
|
| 2017 |
Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. British Journal of Haematology. PMID 28211579 DOI: 10.1111/Bjh.14522 |
0.342 |
|
| 2017 |
Derman BA, Macklis JN, Azeem MS, Sayidine S, Basu S, Batus M, Esmail F, Borgia JA, Bonomi P, Fidler MJ. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. Bmc Cancer. 17: 141. PMID 28209123 DOI: 10.1186/S12885-017-3122-Y |
0.443 |
|
| 2017 |
Kim S, Karo A, Buckingham L, Basu S, Borgia JA, Bonomi P, Batus M, Fidler MJ. Association of KRAS mutations detected via liquid biopsy in metastatic non-small cell lung cancer patients with high levels of FDG-PET SUV. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E20594 |
0.359 |
|
| 2017 |
Fidler MJ, Batus M, Tarhoni I, Sayidine S, Fhied CL, Basu S, Bonomi P, Borgia JA. Circulating biomarkers and outcomes in advanced non-small cell lung cancer patients treated with anti-PD1 (program death 1 receptor) monoclonal antibodies. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E20592 |
0.385 |
|
| 2017 |
Labomascus S, Fughhi I, Bonomi P, Fidler MJ, Borgia JA, Basu S, Hoch MA, Batus M. Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E14530 |
0.417 |
|
| 2017 |
McNeal S, Bitterman P, Bahr JM, Hanafin WP, Sharma S, Basu S, Barua A. Abstract NTOC-100: OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND WITHAFERIN A (ASHWAGANDHA) ENHANCES ANTI-TUMOR IMMUNITY Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-100 |
0.331 |
|
| 2017 |
Lobato GC, Fialkoff JD, Tarhoni I, Lund N, Chukkapalli V, Sayidine S, Fhied CL, Basu S, Lie W, Liptay MJ, Bonomi P, Borgia JA. Abstract 4665: Induction of receptor tyrosine kinase signaling by sera from patients with lung adenocarcinoma Cancer Research. 77: 4665-4665. DOI: 10.1158/1538-7445.Am2017-4665 |
0.305 |
|
| 2017 |
Labomascus S, Fughhi I, Bonomi P, Fidler M, Borgia J, Basu S, Hoch M, Batus M. PUB057 Neutrophil to Lymphocyte Ratio Predicts Survival in Advanced NSCLC Patients Treated with Second-Line PD-1 Immune Checkpoint Inhibitors Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1920 |
0.314 |
|
| 2017 |
Batus M, Kerns S, Savidine S, Fhied C, Basu S, Bonomi P, Borgia J, Fidler M, Shah P. P2.03b-060 Baseline Skeletal Muscle Index (SMI) Values Are Associated with Biomarkers of Insulin Resistance in Stage IV Non-Small Cell Lung Cancer: Topic: Biomarkers Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1341 |
0.359 |
|
| 2017 |
Macklis J, Saleem F, Esmail F, Basu S, Fidler M, Bonomi P, Batus M. P2.03a-006 Frequency of 2 Year PFS Milestone in Stage IV NSCLC Patients Treated with First Line Pemetrexed/Platinum and Pemetrexed Maintenance: Topic: Clinical Trials Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1215 |
0.314 |
|
| 2016 |
Tarhoni I, Fhied C, Pithadia R, Seder CW, Basu S, Liptay M, Borgia JA. MINI01.06: Circulating Angiogenesis Biomarkers are Predictive for Early Stage Non-Small Cell Lung Cancer Progression and Clinical Outcome: Topic: Pathology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S259-S260. PMID 27969454 DOI: 10.1016/J.Jtho.2016.09.021 |
0.402 |
|
| 2016 |
McNeal S, Bitterman P, Bahr JM, Edassery SL, Abramowicz JS, Basu S, Barua A. Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model. Journal of Immunology Research. 2016: 6729379. PMID 27579331 DOI: 10.1155/2016/6729379 |
0.328 |
|
| 2016 |
Medairos RA, Clark J, Holoubek S, Kubasiak JC, Pithadia R, Hamid F, Chmielewski GW, Warren WH, Basu S, Borgia JA, Liptay MJ, Seder CW. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. PMID 27157918 DOI: 10.1016/J.Jtcvs.2016.03.094 |
0.426 |
|
| 2016 |
Geissen NM, Medairos R, Davila E, Basu S, Warren WH, Chmielewski GW, Liptay MJ, Arndt AT, Seder CW. Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. Lung. PMID 27107874 DOI: 10.1007/S00408-016-9882-3 |
0.313 |
|
| 2016 |
Macklis JN, Saleem F, Esmail FM, Basu S, Fidler MJ, Bonomi P, Batus M. Two year progression free survival in stage IV NSCLC patients treated with pemetrexed continuation maintenance. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E20654 |
0.379 |
|
| 2016 |
Rybar DW, Ng R, Fidler MJ, Kerns S, Sayidine S, Basu S, Borgia JA, Dudek AZ, Bonomi P, Shah P, Menchaca M. Cachexia Index utilization in patients with non-small cell lung cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E20642 |
0.395 |
|
| 2016 |
Derman BA, Borgia JA, Fhied CL, Basu S, Batus M, Bonomi P, Fidler MJ. Association of biomarkers of insulin resistance and inflammation with PET CT SUV values in stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E20589 |
0.338 |
|
| 2016 |
Barua A, Bahr JM, Bitterman P, Rosen LE, Bradaric MJ, Sharma S, Basu S, Abramowicz JS. Effect of death receptor 6 (DR6) targeted molecular ultrasound imaging on detection of ovarian tumors at early stage. Journal of Clinical Oncology. 34: e17063-e17063. DOI: 10.1200/Jco.2016.34.15_Suppl.E17063 |
0.303 |
|
| 2016 |
Kim S, Karo A, Basu S, Borgia JA, Bonomi P, Batus M, Fidler MJ. KRAS and P53 mutations and FDG-PET as a measure of glycolytic activity in metastatic non-small cell lung cancer patients. Journal of Clinical Oncology. 34: 9086-9086. DOI: 10.1200/Jco.2016.34.15_Suppl.9086 |
0.366 |
|
| 2016 |
Batus M, Kerns S, Sayidine S, Fhied CL, Basu S, Bonomi P, Borgia JA, Fidler MJ, Shah P. Association of biomarkers of insulin resistance and inflammation with skeletal muscle index (SMI) in stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 10013-10013. DOI: 10.1200/Jco.2016.34.15_Suppl.10013 |
0.372 |
|
| 2016 |
Karmali R, Chukkapalli V, Shah P, Alrifai T, Fughhi IA, Ng R, Basu S, Szymanski K, Venugopal P, Borgia JA. Biologic Pathways of Cancer-Cachexia Syndrome (Muscle and Fat Wasting) Impact Clinical Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma Blood. 128: 1771-1771. DOI: 10.1182/Blood.V128.22.1771.1771 |
0.315 |
|
| 2016 |
Barua A, Bitterman P, Sharma S, Basu S, Bahr JM. Abstract A48: Ovarian tumor-induced immunosuppression of NK cells and its prevention by dietary supplementation of herbal Withaferin A (Ashwagandha). Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A48 |
0.338 |
|
| 2015 |
Seder CW, Kubasiak JC, Pithadia R, Basu S, Fhied C, Tarhoni I, Davila E, Alnajjar H, Chmielewski GW, Warren WH, Liptay MJ, Borgia JA. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. The Annals of Thoracic Surgery. 100: 429-36. PMID 26138771 DOI: 10.1016/J.Athoracsur.2015.04.018 |
0.39 |
|
| 2015 |
Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leukemia & Lymphoma. 1-8. PMID 25735964 DOI: 10.3109/10428194.2015.1022767 |
0.303 |
|
| 2015 |
Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 64: 459-65. PMID 25603775 DOI: 10.1007/S00262-014-1652-6 |
0.344 |
|
| 2015 |
Kubasiak JC, Seder CW, Pithadia R, Basu S, Fhied C, Phillips WW, Daly S, Shersher DD, Yoder MA, Chmielewski G, Edell ES, Maldonado F, Liptay MJ, Borgia JA. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. 149: 727-34.e1-3; discuss. PMID 25312225 DOI: 10.1016/J.Jtcvs.2014.08.085 |
0.374 |
|
| 2015 |
Borgia JA, Bourdon D, Bucci J, Seder CW, Pithadia R, Fhied C, Basu S, Chmielewski G, Liptay MJ. Plasma biomarkers to help guide the management of patients with indeterminate findings during low-dose CT (LDCT) lung cancer screening. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E22264 |
0.328 |
|
| 2015 |
Macklis JN, Fidler MJ, Bonomi P, Basu S, Borgia JA, Azeem MS, Sher D, Batus M. Serial neutrophil to lymphocyte ratios (NLR) in relation to weight change and overall survival in patients (Pts) with metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19143 |
0.422 |
|
| 2015 |
Borgia JA, Pithadia R, Seder CW, Tarhoni I, Basu S, Fhied C, Lie W, Mistry JS, Chmielewski G, Bonomi P, Liptay MJ. The prognostic significance of circulating angiogenesis biomarkers in stage I NSCLC. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13506 |
0.349 |
|
| 2015 |
Rosen LE, Barua A, Bahr JM, Basu S, Sharma S, Edassery SE, Guirguis AS, Bitterman P. Abstract POSTER-BIOL-1343: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) prevents ovarian cancer progression Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1343 |
0.361 |
|
| 2014 |
Daly S, Kubasiak JC, Rinewalt D, Pithadia R, Basu S, Fhied C, Lobato GC, Seder CW, Hong E, Warren WH, Chmielewski G, Liptay MJ, Bonomi P, Borgia JA. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. The Annals of Thoracic Surgery. 98: 1968-75; discussion . PMID 25301368 DOI: 10.1016/J.Athoracsur.2014.06.071 |
0.384 |
|
| 2014 |
Yellapa A, Bitterman P, Sharma S, Guirguis AS, Bahr JM, Basu S, Abramowicz JS, Barua A. Interleukin 16 expression changes in association with ovarian malignant transformation. American Journal of Obstetrics and Gynecology. 210: 272.e1-10. PMID 24380743 DOI: 10.1016/J.Ajog.2013.12.041 |
0.303 |
|
| 2014 |
Barua A, Yellapa A, Bahr JM, Machado SA, Bitterman P, Basu S, Sharma S, Abramowicz JS. Enhancement of ovarian tumor detection with αvβ3 integrin-targeted ultrasound molecular imaging agent in laying hens: a preclinical model of spontaneous ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 24: 19-28. PMID 24304684 DOI: 10.1097/Igc.0000000000000040 |
0.323 |
|
| 2014 |
Borgia JA, Pithadia R, Ibrahem Z, Fhied C, Basu S, Lie W, Fidler MJ, Batus M, Bonomi PD. Potential predictive value of hepatocyte growth factor (HGF) in advanced non-small cell lung cancer (NSCLC) treated with a platinum doublet and bevacizumab. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E22000 |
0.403 |
|
| 2014 |
Azeem MS, Basu S, Melinamani S, Batus M, Pithadia R, Borgia JA, Bonomi P, Fidler MJ. Association of overall survival with weight gain during treatment, initial body mass index (BMI), and glucose intolerance (GI) in advanced non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E19033 |
0.391 |
|
| 2014 |
Gupta N, Bahr JM, Sharma S, Bitterman P, Guirguis AS, Basu S, Barua A. Inhibition of ovarian tumor-associated DJ-1 expression and tumor progression. Journal of Clinical Oncology. 32: e16527-e16527. DOI: 10.1200/Jco.2014.32.15_Suppl.E16527 |
0.381 |
|
| 2014 |
Batus M, Pithadia R, Kubasiak J, Fhied C, Ibrahem Z, Melinamani S, Fughhi I, Lie W, Basu S, Fidler MJ, Bonomi PD, Borgia JA. Differences in circulating angiogenic biomarkers as prognosticator for outcome in bevacizumab-treated nonsquamous non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 32: 11037-11037. DOI: 10.1200/Jco.2014.32.15_Suppl.11037 |
0.432 |
|
| 2014 |
Batus M, Pithadia R, Kubasiak J, Fhied C, Ibrahem Z, Melinamani S, Fughhi I, Lie W, Basu S, Fidler M, Bonomi PD, Borgia JA. Differences in Circulating Angiogenic Biomarkers as Prognosticator for Outcome in Bevacizumab-Treated Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Patients International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.314 |
0.432 |
|
| 2013 |
Barua A, Bradaric MJ, Bitterman P, Abramowicz JS, Sharma S, Basu S, Lopez H, Bahr JM. Dietary supplementation of Ashwagandha (Withania somnifera, Dunal) enhances NK cell function in ovarian tumors in the laying hen model of spontaneous ovarian cancer. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 70: 538-50. PMID 24188693 DOI: 10.1111/Aji.12172 |
0.324 |
|
| 2013 |
Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology. 84: 123-6. PMID 23235386 DOI: 10.1159/000342764 |
0.307 |
|
| 2013 |
Daly S, Rinewalt D, Fhied C, Basu S, Mahon B, Liptay MJ, Hong E, Chmielewski G, Yoder MA, Shah PN, Edell ES, Maldonado F, Bungum AO, Borgia JA. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 31-6. PMID 23201823 DOI: 10.1097/Jto.0B013E31827627F8 |
0.363 |
|
| 2013 |
Pool M, Fidler MJ, Basu S, Mahon B, Buckingham L, Walters KK, Batus M, Hensing TA, Borgia JA, Bonomi PD. Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E19117 |
0.424 |
|
| 2013 |
Fidler MJ, Basu S, Hensing TA, Buckingham L, Pool M, Mahon B, Batus M, Walters KK, Bonomi PD. Thyroid transcription factor 1 (TTF-1) and overall survival in wild type EGFR patients treated with erlotinib. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E19113 |
0.415 |
|
| 2013 |
Barua A, Yellapa A, Grasso SA, Abramowicz JS, Sharma S, Guirguis AS, Basu S, Bitterman P. Expression of glucose-regulated protein 78 (GRP78) and its regulator microrna-181 during the development and progression of ovarian cancer. Journal of Clinical Oncology. 31: 5579-5579. DOI: 10.1200/Jco.2013.31.15_Suppl.5579 |
0.333 |
|
| 2013 |
Hughes T, Iodice GM, Basu S, Bines S, Kaufman H. The role of surgery following incomplete response to high-dose IL-2 (HD IL-2) Journal For Immunotherapy of Cancer. 1: 145. DOI: 10.1186/2051-1426-1-S1-P145 |
0.336 |
|
| 2013 |
Hughes T, Iodice GM, Basu S, Bines S, Kaufman H. Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease Journal For Immunotherapy of Cancer. 1: 105. DOI: 10.1186/2051-1426-1-S1-P105 |
0.332 |
|
| 2013 |
Karmali R, Vita MD, Petrich AM, Nabhan C, Kruczek K, Raizer J, McFarland D, Peace D, Lukas R, Basu S, Gregory SA, Venugopal P. Multicenter Analysis Of Primary Central Nervous System Lymphoma: Patient Characteristics, Treatment Patterns and Survival Blood. 122: 1803-1803. DOI: 10.1182/Blood.V122.21.1803.1803 |
0.347 |
|
| 2013 |
Alongkronrusmee D, Bitterman P, Abramowicz JS, Bahr JM, Basu S, Grasso S, Sharma S, Rotmensch J, Barua A. Abstract 4642: GRP78 in association with VEGFR-2 detects early stage ovarian cancer. Cancer Research. 73: 4642-4642. DOI: 10.1158/1538-7445.Am2013-4642 |
0.365 |
|
| 2013 |
Yellapa A, Bitterman P, Abramowicz JS, Bahr JM, Basu S, Sharma S, Barua A. Abstract 4641: IL-16 in association with VEGFR-2 detect early tumor associated changes in the ovary. Cancer Research. 73: 4641-4641. DOI: 10.1158/1538-7445.Am2013-4641 |
0.324 |
|
| 2013 |
Barua A, Abramowicz JS, Bahr JM, Grasso SA, Sharma S, Basu S, Rotmensch J, Bitterman P. Abstract 3471: Anti-NMP autoantibodies together with serum levels of death receptor 6 (DR6) detect ovarian tumors at early stage . Cancer Research. 73: 3471-3471. DOI: 10.1158/1538-7445.Am2013-3471 |
0.341 |
|
| 2013 |
Yellapa A, Bitterman P, Abramowicz JS, Bahr JM, Sharma S, Basu S, Barua A. Abstract A64: Association of interleukin 16 with early metastasis of ovarian tumors Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A64 |
0.314 |
|
| 2012 |
Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B. 21: 207-13. PMID 23111194 DOI: 10.1097/Pdm.0B013E31825554B2 |
0.355 |
|
| 2012 |
Rinewalt D, Shersher DD, Daly S, Fhied C, Basu S, Mahon B, Hong E, Chmielewski G, Liptay MJ, Borgia JA. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. The Journal of Thoracic and Cardiovascular Surgery. 144: 1344-50; discussion . PMID 22982029 DOI: 10.1016/J.Jtcvs.2012.08.033 |
0.413 |
|
| 2012 |
Barua A, Yellapa A, Bahr JM, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Bitterman P. Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer. Translational Oncology. 5: 260-8. PMID 22937178 DOI: 10.1593/Tlo.12184 |
0.364 |
|
| 2012 |
Khan MF, Bahr JM, Yellapa A, Bitterman P, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Barua A. Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer. Translational Oncology. 5: 85-91. PMID 22496924 DOI: 10.1593/Tlo.11328 |
0.336 |
|
| 2012 |
Yellapa A, Bahr JM, Bitterman P, Abramowicz JS, Edassery SL, Penumatsa K, Basu S, Rotmensch J, Barua A. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 199-207. PMID 22274315 DOI: 10.1097/Igc.0B013E318236A27B |
0.316 |
|
| 2012 |
Braun E, Fidler MJ, Basu S, Gangaram A, Walters KK, Karmali R, Fhied C, Lie W, Borgia JA, Bonomi PD. Panel of serum biomarkers to predict benefit from bevacizumab (BEV) in advanced NSCLC patients. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E21069 |
0.383 |
|
| 2012 |
Fidler MJ, Dave MJ, Basu S, Hensing TA, Pool M, Mahon B, Borgia JA, Walters KK, Escarzaga D, Batus M, Bonomi PD. EGFR gene mutation and epithelial to mensenchymal transition (EMT) markers in advanced NSCLC patients treated with erlotinib. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18117 |
0.373 |
|
| 2012 |
Raj RV, Basu S, Boggio LN, Fung HC, Gregory SA, Venugopal P, Rich ES. Racial disparities in survival of adult T-cell leukemia/lymphoma patients in the United States: A SEER database analysis. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E16503 |
0.303 |
|
| 2012 |
Batus M, Fidler MJ, Walters KK, Pool M, Mahon B, Basu S, Borgia JA, Sher D, Bonomi PD. Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC) patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival (OS). Journal of Clinical Oncology. 30: 7067-7067. DOI: 10.1200/Jco.2012.30.15_Suppl.7067 |
0.429 |
|
| 2012 |
Khan MF, Yellapa A, Bahr J, Bitterman P, Abramowicz J, Basu S, Edassery S, Barua A. Abstract 5415: Expression of immunosuppressive leukocyte inhibitory immunoglobulin like transcript 3(ILT3) receptors increases with the development and progression of ovarian tumors Cancer Research. 72: 5415-5415. DOI: 10.1158/1538-7445.Am2012-5415 |
0.338 |
|
| 2012 |
Yellapa A, Khan MF, Bahr JM, Bitterman P, Abramowicz JS, Basu S, Edassery SL, Barua A. Abstract 3646: Expression of death receptor 6 (DR6) increases in association with ovarian tumor development and progression Cancer Research. 72: 3646-3646. DOI: 10.1158/1538-7445.Am2012-3646 |
0.344 |
|
| 2012 |
Pool MD, Kaiser KA, Basu S, Borgia JA, Fidler MJ, Bonomi P. Abstract 3403: E-cadherin and vimentin patterns by immunohistochemistry identify epithelial and mesenchymal phenotypes in lung adenocarcinoma Cancer Research. 72: 3403-3403. DOI: 10.1158/1538-7445.Am2012-3403 |
0.368 |
|
| 2012 |
Barua A, Qureshi T, Bitterman P, Bahr JM, Basu S, Edassery SL, Abramowicz JS. Abstract 2455: Molecular targeted imaging of vascular endothelial growth factor receptor (VEGFR)-2 and anti-NMP autoantibodies detect ovarian tumor at early stage Cancer Research. 72: 2455-2455. DOI: 10.1158/1538-7445.Am2012-2455 |
0.313 |
|
| 2012 |
Rouhi O, Arvanitis L, Marconi P, Kaiser K, Basu S, Mahon B, Pool M, Usha L, Liptay M, Bonomi P, Borgia J. Abstract 2404: Correlation of OGlcNAc modification components and EMT/Stem cell markers in lung adenocarcinoma Cancer Research. 72: 2404-2404. DOI: 10.1158/1538-7445.Am2012-2404 |
0.328 |
|
| 2012 |
Rinewalt D, Daly S, Fhied C, Basu S, Lie W, Hayes D, Mahon B, Deng Y, Bonomi P, Usha L, Liptay MJ, Borgia JA. Abstract 1730: Expression of serum biomarkers related to epithelial-to-mesenchymal transition in non-small cell lung cancer recurrence Cancer Research. 72: 1730-1730. DOI: 10.1158/1538-7445.Am2012-1730 |
0.45 |
|
| 2011 |
McFarland DC, Batus M, Buckingham L, Coon J, Basu S, Fidler MJ, Walters KK, Borgia JA, Bonomi PD. Increased Bcl-2 expression is associated with Bax promoter hypermethylation in neuroendocrine carcinoma (NEC) of the lung. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21136. PMID 28022955 DOI: 10.1200/Jco.2011.29.15_Suppl.E21136 |
0.362 |
|
| 2011 |
Pool MD, Fidler MJ, Kaiser-Walters KA, Basu S, Braun E, Buckingham L, Hensing TA, Bonomi PD. Histologic subtyping and tumor stromal responses in advanced-stage lung adenocarcinoma and their relationship to survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21135. PMID 28022954 DOI: 10.1200/Jco.2011.29.15_Suppl.E21135 |
0.399 |
|
| 2011 |
Batus M, Mohajer R, Pach D, Basu S, Fidler MJ, Bonomi PD. Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18047. PMID 28020805 DOI: 10.1200/Jco.2011.29.15_Suppl.E18047 |
0.335 |
|
| 2011 |
Fidler MJ, Morrison LE, Basu S, Buckingham L, Walters K, Batus M, Jacobson KK, Jewell SS, Coon J, Bonomi PD. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. British Journal of Cancer. 105: 1920-6. PMID 22095222 DOI: 10.1038/Bjc.2011.494 |
0.392 |
|
| 2011 |
Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi O, Mahon B, Coon JS, Warren WH, Faber LP, Hong E, Bonomi P, Liptay MJ, Borgia JA. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. The Annals of Thoracic Surgery. 92: 1805-11; discussion . PMID 21945224 DOI: 10.1016/J.Athoracsur.2011.06.058 |
0.398 |
|
| 2011 |
Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, Faber LP. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. The Annals of Thoracic Surgery. 92: 233-41; discussion 2. PMID 21620372 DOI: 10.1016/J.Athoracsur.2011.03.001 |
0.372 |
|
| 2011 |
Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1079-86. PMID 21532501 DOI: 10.1097/Jto.0B013E3182199A7C |
0.424 |
|
| 2011 |
Barua A, Bitterman P, Bahr JM, Basu S, Sheiner E, Bradaric MJ, Hales DB, Luborsky JL, Abramowicz JS. Contrast-enhanced sonography depicts spontaneous ovarian cancer at early stages in a preclinical animal model. Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. 30: 333-45. PMID 21357555 DOI: 10.7863/Jum.2011.30.3.333 |
0.345 |
|
| 2011 |
Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon JS, DeCresce D, Thimothy L, Walters KA, Fhied C, Chang C, Chen SH, Faber LP, Bonomi P, Liptay MJ, et al. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. International Journal of Cancer. Journal International Du Cancer. 129: 133-42. PMID 20824709 DOI: 10.1002/Ijc.25644 |
0.398 |
|
| 2011 |
Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 71: 186-90. PMID 20570389 DOI: 10.1016/J.Lungcan.2010.05.006 |
0.413 |
|
| 2011 |
Borgia JA, Frankenberger C, Basu S, Rouhi O, Fidler MJ, Batus M, Fhied CL, Dalovisio AP, Lie W, Maheshwari R, Hayes D, Coon J, Bonomi P. Abstract 339: Rational selection of biomarkers to help direct erlotinib treatment for advanced non-small cell lung cancer (NSCLC) Cancer Research. 71: 339-339. DOI: 10.1158/1538-7445.Am2011-339 |
0.434 |
|
| 2010 |
Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA. A multi-analyte serum test for the detection of non-small cell lung cancer. British Journal of Cancer. 103: 1221-8. PMID 20859284 DOI: 10.1038/Sj.Bjc.6605865 |
0.435 |
|
| 2010 |
Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3452-62. PMID 20570928 DOI: 10.1158/1078-0432.Ccr-09-3192 |
0.445 |
|
| 2010 |
Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. International Journal of Cancer. 126: 1630-9. PMID 19795445 DOI: 10.1002/Ijc.24896 |
0.368 |
|
| 2010 |
Kim AW, Faber LP, Warren WH, Shah ND, Basu S, Liptay MJ. Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. The Journal of Thoracic and Cardiovascular Surgery. 139: 606-11. PMID 19709677 DOI: 10.1016/J.Jtcvs.2009.05.044 |
0.406 |
|
| 2010 |
Frankenberger C, Basu S, Bild N, Potti A, Raponi M, Wang Y, Beer DG, Coon J, Bonomi P, Borgia JA. Expression profiles associated with disease progression in non-small cell lung cancer. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E21103 |
0.439 |
|
| 2010 |
Batus M, McFarland DC, Coon J, Basu S, Pool M, Myint R, Walters KK, Fidler MJ, Bonomi PD. Mcl-1 and bcl-2 expression in neuroendocrine carcinoma (NEC) and potential for new therapeutic target. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E21039 |
0.387 |
|
| 2010 |
Gielda BT, Marsh JC, Zusag TW, Khan AJ, Liptay MJ, Basu S, Faber P, Fidler MJ, Abrams RA, Bonomi PD. Evaluation of pre- and post-treatment related to outcome in advanced non-small cell lung cancer (NSCLC) patients treated with split course concurrent chemoradiotherapy (CRT) followed by resection: A single-institution series of 49 patients. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E17510 |
0.399 |
|
| 2010 |
Rouhi O, Kaiser-Walters KA, Escarzaga D, Steker D, Basu S, Liptay MJ, Gattuso P, Bonomi PD, Coon J, Borgia JA. Expression of sonic hedgehog and its receptor patched in non-small cell lung cancer. Journal of Clinical Oncology. 28: 7620-7620. DOI: 10.1200/Jco.2010.28.15_Suppl.7620 |
0.414 |
|
| 2010 |
Karmali R, Fidler MJ, Cela I, Olmsted G, Rouhi O, Basu S, Walters KK, Coon J, Bonomi P, Borgia JA. Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy. Journal of Clinical Oncology. 28: 7553-7553. DOI: 10.1200/Jco.2010.28.15_Suppl.7553 |
0.357 |
|
| 2010 |
Hensing TA, Fidler MJ, Wong F, Polish A, Watkin W, Basu S, Kaiser-Walters KA, Pool M, Coon J, Bonomi P. The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib. Journal of Clinical Oncology. 28: 7552-7552. DOI: 10.1200/Jco.2010.28.15_Suppl.7552 |
0.381 |
|
| 2010 |
Shah NB, Fidler MJ, Walters KK, Braun E, Basu S, Harasty H, Coon J, Pool M, Hensing TA, Bonomi PD. Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib. Journal of Clinical Oncology. 28: 7550-7550. DOI: 10.1200/Jco.2010.28.15_Suppl.7550 |
0.401 |
|
| 2010 |
Fidler MJ, Basu S, Kaiser-Walters KA, Hadziahmetovic E, Batus M, Steker D, Coon J, Bonomi P. Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation. Journal of Clinical Oncology. 28: 7034-7034. DOI: 10.1200/Jco.2010.28.15_Suppl.7034 |
0.442 |
|
| 2010 |
Vercillo MS, Farlow EC, Coon J, Basu S, Kim AW, Faber P, Bonomi P, Liptay MJ, Borgia JA. A multi-analyte serum test for the early diagnosis of non-small cell lung cancer. Journal of Clinical Oncology. 28: 1554-1554. DOI: 10.1200/Jco.2010.28.15_Suppl.1554 |
0.393 |
|
| 2010 |
Basu S, Tiwari RC. Breast cancer survival, competing risks and mixture cure model: a Bayesian analysis Journal of the Royal Statistical Society Series a-Statistics in Society. 173: 307-329. DOI: 10.1111/J.1467-985X.2009.00618.X |
0.329 |
|
| 2009 |
Batus M, Myint R, Coon J, Basu S, Kaiser K, Fidler M, Bonomi P. N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e22157. PMID 27963548 DOI: 10.1200/Jco.2009.27.15_Suppl.E22157 |
0.325 |
|
| 2009 |
Fidler MJ, Seba A, Farlow EC, Basu S, Kaiser-Walters K, Steker D, Coon J, Kim AW, Bonomi P, Faber LP. Tumor survivin expression in locally advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemoradiation followed by surgical resection. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7595. PMID 27963425 DOI: 10.1200/Jco.2009.27.15_Suppl.7595 |
0.442 |
|
| 2009 |
Myint R, Batus M, Bonomi P, Gattuso P, Warren WH, Liptay M, Faber P, Basu S, Xu X, Kim AW. Xanthine oxidoreductase and chemosensitivity in non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11077. PMID 27963201 DOI: 10.1200/Jco.2009.27.15_Suppl.11077 |
0.369 |
|
| 2009 |
Liptay MJ, Basu S, Hoaglin MC, Freedman N, Faber LP, Warren WH, Hammoud ZT, Kim AW. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. Journal of Surgical Oncology. 100: 703-7. PMID 19798693 DOI: 10.1002/Jso.21407 |
0.437 |
|
| 2009 |
Milman S, Kim AW, Warren WH, Liptay MJ, Miller C, Basu S, Faber LP. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. The Annals of Thoracic Surgery. 88: 945-50; discussion 9. PMID 19699925 DOI: 10.1016/J.Athoracsur.2009.05.084 |
0.384 |
|
| 2009 |
Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, Bonomi P, Liptay MJ. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? The Annals of Thoracic Surgery. 88: 937-43; discussion 9. PMID 19699924 DOI: 10.1016/J.Athoracsur.2009.04.102 |
0.372 |
|
| 2009 |
Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH, Bonomi P, Liptay MJ. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 338-47. PMID 19190517 DOI: 10.1097/Jto.0B013E3181982Abf |
0.411 |
|
| 2009 |
Ghosh P, Basu S, Tiwari RC. Bayesian Analysis of Cancer Rates From SEER Program Using Parametric and Semiparametric Joinpoint Regression Models Journal of the American Statistical Association. 104: 439-452. DOI: 10.1198/Jasa.2009.0038 |
0.32 |
|
| 2009 |
Farlow EC, Kim AW, Basu S, Panicker S, Fhied C, Rouhi O, Kaiser KA, Faber LP, Warren WH, Bonomi P, Coon JS, Borgia JA. 4. Serum Screening Test for Non-Small Cell Lung Cancer Journal of Surgical Research. 151: 174. DOI: 10.1016/J.Jss.2008.11.015 |
0.363 |
|
| 2008 |
Kim AW, Faber LP, Warren WH, Saclarides TJ, Carhill AA, Basu S, Choh MS, Liptay MJ. Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 144: 712-7; discussion 71. PMID 18847658 DOI: 10.1016/J.Surg.2008.07.007 |
0.329 |
|
| 2008 |
Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2088-94. PMID 18381949 DOI: 10.1158/1078-0432.Ccr-07-4013 |
0.424 |
|
| 2008 |
Sarkar SK, Patra NB, Goswami J, Basu S. Comparative study of efficacy and toxicities of cisplatin vs vinorelbine as radiosensitisers in locally advanced head and neck cancer. The Journal of Laryngology and Otology. 122: 188-92. PMID 17445333 DOI: 10.1017/S0022215107007645 |
0.309 |
|
| 2008 |
Liptay MJ, Basu S, Hoaglin MC, Freedman N, Faber LP, Warren WH, Hammoud ZT, Kim AW. Diffusion Lung Capacity For Carbon Monoxide (Dlco) Is An Independent Predictor For Long-Term Survival After Curative Lung Resection For Lung Cancer Chest. 134. DOI: 10.1378/Chest.134.4_Meetingabstracts.S36002 |
0.36 |
|
| 2008 |
Kim AW, Shah ND, Faber LP, Warren WH, Basu S, Liptay MJ. The Indication For Bilobectomy In Non-Small Cell Lung Cancer Matters Chest. 134: 76. DOI: 10.1378/Chest.134.4_Meetingabstracts.P76002 |
0.382 |
|
| 2008 |
Fidler MJ, Basu S, Buckingham L, Kaiser K, McCormack SE, Coon JS, Bonomi PD. Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib Journal of Clinical Oncology. 26: 8036-8036. DOI: 10.1200/Jco.2008.26.15_Suppl.8036 |
0.379 |
|
| 2008 |
Batus M, Fidler MJ, Basu S, Coon JS, Buckingham L, Kaiser-Walters K, McCormack SE, Bonomi PD. Frequency of insulin-like growth factor 1 (IGFR-1) expression and correlation with clinical and selected molecular parameters in advanced non-small cell lung cancer (NSCLC) patients (pts) Journal of Clinical Oncology. 26: 22080-22080. DOI: 10.1200/Jco.2008.26.15_Suppl.22080 |
0.378 |
|
| 2008 |
Buckingham L, Faber LP, Kim AW, Kaiser K, Barger C, Basu S, Liptay MJ, Bonomi PD, Coon JS. Tumor suppressor gene CpG site methylation and outcome in surgically treated stage I-II non-small cell lung cancer patients Journal of Clinical Oncology. 26: 11035-11035. DOI: 10.1200/Jco.2008.26.15_Suppl.11035 |
0.358 |
|
| 2007 |
Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM, Bonomi P. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 414-22. PMID 17473657 DOI: 10.1097/01.Jto.0000268675.02744.B0 |
0.369 |
|
| 2007 |
Borgia JA, Frankenberger C, Basu S, Kaiser KA, McCormack SE, Faber LP, Liptay MJ, Bonomi PD, Coon JS. P2-055: A serum proteomic analysis of lung squamous cell carcinoma. Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283519.07042.0C |
0.328 |
|
| Show low-probability matches. |